Crossmark

The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study

Crossref DOI link: https://doi.org/10.1016/j.abd.2026.501335

Published Print: 2026-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pehlivan Ulutaş, Gizem https://orcid.org/0000-0002-5906-3976
Özkök Akbulut, Tuğba

Polat Ekinci, Algün
License Information

Text and Data Mining valid from 2026-05-01

Text and Data Mining valid from 2026-05-01

Version of Record valid from 2026-03-28
More Information

This article is maintained by: Elsevier

Article Title: The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2026.501335

Content Type: article

Copyright: © 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.